DUX4 and Facioscapulohumeral dystrophy: DUX4 target candidates have been silenced in primary FSHD muscle cells using bromodomain and extra-terminal domain (BET) inhibitors (BETi) targeting all the proteins of the BET family (Figure 4) [102].